sellWeak cluster of 310b5-1 plan
Ashleigh Palmer sold $765k of PRVB
Director and CEO at Provention Bio, Inc.. 75,835 shares at an average of $10.09, traded Feb 10, 2023, filed Feb 14, 2023.
Warning score
27Value
$765k
75,835 shares
Holdings after
2,570,050
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +22Trade size$765k at market
- 0Share of holdings soldSold 2.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001493152-23-005076, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2023 | MOption exercise Common Stock | +50,000 | $2.50 | $125k | 2,620,050 | Feb 14, 2023 |
| Feb 10, 2023 | SOpen-market sale Common Stock10b5-1 | -50,000 | $10.11 | $506k | 2,570,050 | Feb 14, 2023 |
| Feb 13, 2023 | MOption exercise Common Stock | +25,835 | $2.50 | $65k | 2,595,885 | Feb 14, 2023 |
| Feb 13, 2023 | SOpen-market sale Common Stock10b5-1 | -25,835 | $10.04 | $259k | 2,570,050 | Feb 14, 2023 |
| Feb 10, 2023 | MOption exercise Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 467,555 | Feb 14, 2023 |
| Feb 13, 2023 | MOption exercise Stock Option (right to buy)derivative | -25,835 | $0.00 | $0 | 441,720 | Feb 14, 2023 |
Related signals
Other insiders at Provention Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | PRVBsell Provention Bio, Inc. | Sessa Capital (Master), L.P. owner | $53M 2,190,549 shares | -12% | |
| 36Weak | Provention Bio, Inc. | Jason Hoitt Chief Commercial Officer | $45k 4,500 shares | -100% | |
| 17Weak | Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $767k 75,985 shares | -5% | |
| 8Weak | Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $247k 24,015 shares | -2% | |
| 18Weak | Provention Bio, Inc. | Ashleigh Palmer Director and CEO | $248k 24,165 shares | -1% | |
| 57Moderate | Provention Bio, Inc. | Sessa Capital (Master), L.P. owner | $28M 3,000,000 shares | -20% | |
| 30Weak | PRVBsell Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $1.9M 187,000 shares | -11% | |
| 10Weak | PRVBsell Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $107k 10,674 shares | -1% | |
| 0Weak | PRVBsell Provention Bio, Inc. | Francisco Leon Chief Scientific Officer | $19k 1,943 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.